Skip to main content
AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.60%0700.HK-5.61%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.14%ORCL-0.97%3988.HK-0.20%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.49%0857.HK-1.46%UNH-10.21%1288.HK-1.06%PM-0.85%0005.HK-1.88%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.70%AUDUSD-1.54%EURAUD+1.06%AUDCHF-1.05%AUDCAD-1.01%AUDNZD-1.00%GBPAUD+0.97%GBPJPY-0.74%NZDJPY-0.72%CADJPY-0.70%EURJPY-0.68%AUDSGD-0.66%CHFJPY-0.66%AUDDKK-0.61%GBPUSD-0.56%USDCAD+0.54%NZDUSD-0.54%USDCHF+0.53%AUDNOK-0.51%EURUSD-0.50%GBPTRY+0.41%NZDMXN+0.38%USDMXN+0.33%GBPHKD+0.32%USDZAR+0.29%GBPMXN-0.28%EURZAR+0.22%USDTRY+0.21%USDTHB+0.21%USDJPY-0.18%GBPZAR+0.18%CHFNOK+0.18%USDILS+0.16%USDNOK+0.16%USDCNH-0.12%NOKJPY-0.12%CHFSEK+0.11%EURNOK+0.10%USDPLN+0.10%USDSEK+0.10%EURCNH-0.09%GBPSGD-0.09%NZDSGD+0.08%EURGBP+0.07%EURHKD-0.07%USDDKK+0.06%PLNJPY-0.06%EURSGD-0.05%NZDCHF-0.05%EURCZK+0.04%EURPLN+0.04%EURSEK+0.04%SGDJPY+0.04%GBPCAD-0.04%EURNZD+0.04%GBPCHF-0.04%USDCOP-0.04%EURCAD+0.04%EURCHF+0.03%CHFSGD+0.03%NZDCAD-0.02%CADCHF-0.02%GBPNZD-0.02%USDHKD-0.01%USDSGD+0.01%EURDKK0.00%XNGUSD-0.70%UKOIL+0.65%W1-0.55%USOIL+0.51%XAGUSD+0.50%GAGUSD+0.50%GAUUSD+0.48%XAUUSD+0.48%C1-0.41%S1-0.29%COTTON+0.24%HG1-0.10%BTCUSD-3.45%ETHUSD+57.77%USDTUSD-0.02%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.83%ZECUSDT-6.47%XMRUSDT-1.65%DOGEUSD+55.95%LINKUSD-3.21%XLMUSD-3.67%BCHUSDT-3.36%LTCUSD+47.50%UNIUSD-2.76%SUIUSD-3.02%TONUSD+59.18%HBARUSDT-4.80%TAOUSDT-2.98%AAVEUSD-3.50%ONDOUSDT-5.26%ICPUSDT-1.91%DOTUSDT-3.76%WLDUSDT-3.57%ARBUSDT-5.15%ATOMUSDT-2.31%INJUSDT-7.31%STXUSDT-2.75%PYTHUSDT-0.66%TIAUSDT-3.37%FETUSDT-4.31%JUPUSDT+0.63%SEIUSDT-4.48%GRTUSDT-3.17%OPUSDT-2.63%IOTAUSDT-2.43%POLUSDT-1.89%WIFUSDT-2.98%AXSUSDT-2.62%EOSUSDT-4.17%IMXUSDT-3.36%FARTCOINUSDT-6.14%GALAUSDT-2.38%DYDXUSDT-2.38%ORDIUSDT-2.50%NOTUSDT+0.86%RONINUSDT-2.92%AAPL+0.64%MSFT+1.07%NVDA+0.64%GOOGL+0.80%AMZN+1.46%SPCX+1.27%TSM+0.81%AVGO+3.64%META+0.81%TSLA+0.74%LLY-2.33%WMT-0.13%AMD+5.31%SKHY-0.11%JPM-1.77%BRK-B-2.07%MU+1.55%V-0.37%JNJ-2.15%XOM-3.97%MA-0.37%ASMLa+1.94%ABBV-2.33%COST-1.21%1398.HK-0.60%0700.HK-5.61%KO-0.71%CVX-4.74%PG-0.83%CSCO+2.18%0939.HK-0.14%ORCL-0.97%3988.HK-0.20%GE+0.52%BAC-1.07%HD-0.40%1816.HK-26.49%0857.HK-1.46%UNH-10.21%1288.HK-1.06%PM-0.85%0005.HK-1.88%NVS-2.46%HSBA.L-2.00%INTC-0.91%MS-1.29%AMAT+0.88%AP2d+2.23%AZN-1.93%TXN-1.16%AUDJPY-1.70%AUDUSD-1.54%EURAUD+1.06%AUDCHF-1.05%AUDCAD-1.01%AUDNZD-1.00%GBPAUD+0.97%GBPJPY-0.74%NZDJPY-0.72%CADJPY-0.70%EURJPY-0.68%AUDSGD-0.66%CHFJPY-0.66%AUDDKK-0.61%GBPUSD-0.56%USDCAD+0.54%NZDUSD-0.54%USDCHF+0.53%AUDNOK-0.51%EURUSD-0.50%GBPTRY+0.41%NZDMXN+0.38%USDMXN+0.33%GBPHKD+0.32%USDZAR+0.29%GBPMXN-0.28%EURZAR+0.22%USDTRY+0.21%USDTHB+0.21%USDJPY-0.18%GBPZAR+0.18%CHFNOK+0.18%USDILS+0.16%USDNOK+0.16%USDCNH-0.12%NOKJPY-0.12%CHFSEK+0.11%EURNOK+0.10%USDPLN+0.10%USDSEK+0.10%EURCNH-0.09%GBPSGD-0.09%NZDSGD+0.08%EURGBP+0.07%EURHKD-0.07%USDDKK+0.06%PLNJPY-0.06%EURSGD-0.05%NZDCHF-0.05%EURCZK+0.04%EURPLN+0.04%EURSEK+0.04%SGDJPY+0.04%GBPCAD-0.04%EURNZD+0.04%GBPCHF-0.04%USDCOP-0.04%EURCAD+0.04%EURCHF+0.03%CHFSGD+0.03%NZDCAD-0.02%CADCHF-0.02%GBPNZD-0.02%USDHKD-0.01%USDSGD+0.01%EURDKK0.00%XNGUSD-0.70%UKOIL+0.65%W1-0.55%USOIL+0.51%XAGUSD+0.50%GAGUSD+0.50%GAUUSD+0.48%XAUUSD+0.48%C1-0.41%S1-0.29%COTTON+0.24%HG1-0.10%BTCUSD-3.45%ETHUSD+57.77%USDTUSD-0.02%XRPUSD+52.58%SOLUSD+57.55%TRXUSDT+0.83%ZECUSDT-6.47%XMRUSDT-1.65%DOGEUSD+55.95%LINKUSD-3.21%XLMUSD-3.67%BCHUSDT-3.36%LTCUSD+47.50%UNIUSD-2.76%SUIUSD-3.02%TONUSD+59.18%HBARUSDT-4.80%TAOUSDT-2.98%AAVEUSD-3.50%ONDOUSDT-5.26%ICPUSDT-1.91%DOTUSDT-3.76%WLDUSDT-3.57%ARBUSDT-5.15%ATOMUSDT-2.31%INJUSDT-7.31%STXUSDT-2.75%PYTHUSDT-0.66%TIAUSDT-3.37%FETUSDT-4.31%JUPUSDT+0.63%SEIUSDT-4.48%GRTUSDT-3.17%OPUSDT-2.63%IOTAUSDT-2.43%POLUSDT-1.89%WIFUSDT-2.98%AXSUSDT-2.62%EOSUSDT-4.17%IMXUSDT-3.36%FARTCOINUSDT-6.14%GALAUSDT-2.38%DYDXUSDT-2.38%ORDIUSDT-2.50%NOTUSDT+0.86%RONINUSDT-2.92%
AP

Arrowhead Pharmaceuticals, Inc. (ARWR)

NASDAQ • Healthcare

$43.11
+$0.11 (+0.3%)
Market closed

Last close at November 18, 2026 at 21:00 UTC

Open$42.72
Day Range$42.46 - $44.04
Avg. Volume (3M)2M
Market Cap$6B
52 Week Range
$37.06$95.49
Next EarningsIn 77 daysFeb 4, 2027

Metrics Over Time

Where the Money Goes

Q3 2026
Revenueeverything earned$37.7M100%
Gross Profitminus cost of goods$35.9M95%

Fundamentals & Financials

Revenue (TTM)
$450.8M
Net Income (TTM)
-$724.2M
EPS (TTM)
-$5.09
ROA (TTM)
-41.66%
Current Ratio
4.14
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

+14.7%Q2 2026-$0.93
-6.3%Q3 2026-$1.36
-100.0%Q4 2026-$3.04
Next

Feb 4

in 77 daysQ1 2027

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q4 2026
Miss -100.0%

Arrowhead Pharmaceuticals’ revenue fell year over year in the fourth fiscal quarter of 2026, based on preliminary results reported November 12, 2026, with revenue down 85.3% to about $37.8 million from roughly $256.5 million a year ago. Gross profit came in at about $29.0 million, putting gross margin at ~77%, as the company continued to generate revenue while investing across its RNA interference therapeutics pipeline. Consensus for the next period calls for EPS of -$1.45 on revenue of $45.0 million.

View full earnings history

About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is a biotechnology company that develops RNA interference medicines for complex diseases, with activity centered in the United States. In FY2025, the company recorded $829.4 million in revenue as it advanced a pipeline spanning liver, cardiometabolic, pulmonary, oncology, neuromuscular, inflammatory, and infectious-disease programs.

Name
Arrowhead Pharmaceuticals, Inc.
CEO
Christopher R. Anzalone
Industry
Healthcare
Year Founded
1989
Employees
1,059

Today's Snapshot

AI-generated

The day ended with ARWR slightly higher at 43.11, while its sector was weaker. Arrowhead Pharmaceuticals said new prescriptions for its FCS drug REDEMPLO rose 63% sequentially in its U.S. launch.

Trading Volume

Below 10d avg (2.9M)

2.1M

vs S&P 500 Today

Outperforming Market

+0.54%

Updated: November 18, 2026 at 21:12 UTC

Technical Indicators

2 Buy0 Neutral6 Sell
ARWR shows pronounced downside dynamics despite deeply oversold momentum indicators; a very low RSI and extreme stochastic readings point to oversold conditions, yet MACD and short-term momentum remain negative and the ADX signals a strong trending move to the downside. The current price is substantially below its medium- and long-term moving averages, and on-balance volume is heavily negative, suggesting sustained selling rather than a transient dip. The classic pivot lies essentially at the market, offering little near-term support. Technical takeaway: Strong Sell — strong downtrend with oversold readings but continued distribution and bearish momentum.
All signals
  • EMA (5 indicators)$48.27 - $66.76
    Sell
  • RSI (14)21.29
    Buy
  • Stochastic %K (14, 3, 3)3.54
    Buy
  • MACD Level (12, 26)-5.04
    Sell
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.